Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (1684)	11/10/2014 11:52:13 PM
From: Miljenko Zuanic	Respond to of 3559

I understand what you are saying. I am bit expanding thinking, what may influence future cardiologists opinion and FDA view how to review/police new LDL-C lowering drugs? Appears that MRK (10Q, reading between the lines) will not file for expanded indications, so fundamental question: “lower is better” remain unanswered by IMROVE-IT trial results, regardless of is it ITT or PP analysis. PP analysis may (and probably will) improve results, but ~9% relative difference (for 6-10%/2 year or lower event rate) is too small ( AMG and PFE are increasing pts#) to be accounted as true “medical” benefit. However, sub-group analysis may indicate that further LDL-C reduction (<50 mg/dL) is warranted (greater event rate %-reduction per additional each 10 mg/dL LDLC reduction) and new drugs based on PCKL9 target may bring significant additional benefit??? I wish that they are testing antibody alone against statins, because I believe that those dugs works better (and cleaner) than statins.